Chief Growth Officer Adds $1.25M More — Third Purchase in Three Days
HELP has more than doubled off its 52-week low of $3.76.
Summary
Cybin's Chief Growth Officer Paul Glavine bought $1.25M more stock at $12.47, his third open-market purchase in three days totaling ~$3.47M.
Key Events · Ownership and Investor Activity · HELP
-
Third Consecutive Insider Purchase
Chief Growth Officer Paul Glavine bought 100,000 shares at $12.47 on 2026-09-08, spending $1,247,190 — his third open-market purchase in three days.
-
Three-Day Accumulation Total
Combined with $1.04M on 2026-09-09 and $1.18M on 2026-09-10, Glavine has deployed approximately $3.47M in three days, representing roughly 90% of the company's market cap.
-
Voluntary Disclosure
The Form 4 states it is filed voluntarily because Glavine is not subject to Section 16 reporting requirements, making the disclosure a deliberate transparency move.
-
Post-Transaction Holdings
Glavine now directly holds 4,271,252 shares, with an additional 230,941 shares held indirectly through the PLG Family Trust.
Analysis · HELP · Life Sciences
Paul Glavine, Cybin's Chief Growth Officer, bought another 100,000 shares at $12.47 on September 8, spending $1,247,190. This is his third open-market purchase in three days, following $1.04M on September 9 and $1.18M on September 10, bringing his three-day total to roughly $3.47M. The transaction represents approximately 90% of the company's market cap — an extraordinary personal commitment from a senior executive. The filing notes it is being made voluntarily, as Glavine is not subject to Section 16 reporting requirements, which makes the disclosure itself a deliberate signal of conviction. Against the backdrop of Cybin's $148M net loss and $131.7M cash burn in fiscal 2026, this insider accumulation stands out as a strong vote of confidence in the company's clinical pipeline, particularly the HLP003 Phase 3 program for major depressive disorder.
How filings like this one have moved
In the 30 days to Sep 11, 2026, 42.4% of the 517 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.47%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, HELP was trading at $13.10 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.4M. The 52-week trading range was $3.76 to $14.35. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.